Navigation Links
CuraGen Reports Third Quarter 2008 Financial Results
Date:11/3/2008

- Provides financial guidance through second quarter of 2009 -

- Announces partnership intentions around CR011-vcMMAE -

- Conference call to be held today at 11:00 am ET -

BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), today reported its financial results for the third quarter of 2008.

During the three month period ended September 30, 2008, CuraGen utilized $3.6 million of cash for operations and ended the quarter with $91.4 million of cash and investments. CuraGen expects to utilize an average of $3 to $4 million of cash per quarter through June 2009. The company expects to end the fourth quarter of 2008 with approximately $87 to $89 million in cash and investments, and end the second quarter of 2009 with approximately $79 to $81 million in cash and investments. CuraGen is also pursuing partnership opportunities around CR011-vcMMAE.

"Since the beginning of 2007, we have systematically strengthened our net cash position by $84 million and reduced our cash burn by 73%. We have sold clinical programs and non-core assets generating $129 million, repurchased debt of $91 million at a discount of $17 million and reduced the operating burn from $13.3 million in the first quarter of 2007 to $3.6 million in the third quarter of 2008. We are now in a position to take advantage of our prudent actions in what has become a financially-distressed environment," commented Dr. Timothy M. Shannon, President and Chief Executive Officer.

For the quarter ended September 30, 2008, CuraGen reported a net loss of $4.0 million, or $0.07 per share, compared to a loss of $9.9 million, or $0.18 per share, for the same period in 2007. For the nine months ended September 30
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
2. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
3. CuraGen to Present at the BIO CEO & Investor Conference
4. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
5. CuraGen Corporation Receives Notification from NASDAQ
6. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
7. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
8. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
9. CuraGen Appoints Clinical Oncologist as VP of Medical Development
10. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
11. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... 25 Years of Life ... Sciences Industry Experience, RANCHO CORDOVA, Calif., Aug. ... innovative products that,process and store adult stem cells, said today that ... America, has been named to the Company,s Board of,Directors. Her appointment ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, will announce its second quarter 2008,financial and ... 12,2008. The Company will host a conference call ... day at 4:30 p.m., Eastern Time., Participants ...
... $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48, ... WPI ), a leading specialty pharmaceutical,company, today reported financial ... Second Quarter 2008 Results, Net revenue for the ... $60.3 million, or $0.53 per diluted share. Net income ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... were made whole again by bone tissue grown from ... defects (defects that would not otherwise heal on their ... forms the skull, is a vivid demonstration of new ... use hESCs for tissue regeneration. Using mesenchymal ...
... (December 1, 2007) Damaged or defective genes have ... cancers. Over the past decade, however, scientists have discovered ... off and can cause cancer without any changes in ... poorly understood. Researchers in the laboratory of ...
... Water chemistry and mineralogy are scientific fields that have ... technologies. The boundary of water and rock, however, is ... field of nanoparticle science. Scientists are discovering that ... and engineered water chemistry and systems differently than similar ...
Cached Biology News:Human embryonic stem cell -- derived bone tissue closes massive skull injury 2DNA methylation shown to promote development of colon tumors 2DNA methylation shown to promote development of colon tumors 3Between water and rock -- a new science 2Between water and rock -- a new science 3Between water and rock -- a new science 4Between water and rock -- a new science 5
...
... siSolutions siRNA Custom Synthesis Service ... duplex RNA to knockdown any ... (19 RNA base pairs with ... 27-mers, or other lengths of ...
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
...
Biology Products: